Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Retirees Banking on Quarterly Income Choose HDV Over Growth Funds for Its Defensive Holdings
09:03am, Thursday, 18'th Dec 2025
When income matters more than growth, retirees turn to funds that deliver quarterly checks without volatility. The iShares Core High Dividend ETF (NYSEARCA:HDV) yields 3.3%, triple the S&P 500's 1.03%
- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - Appro
5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments
07:19am, Thursday, 18'th Dec 2025
Social Security's cost-of-living adjustments swing wildly year to year. The 2025 COLA came in at 2.5%, down from 3.2% in 2024 and 8.7% in 2023. For retirees counting on predictable income growth, this
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
02:09am, Thursday, 18'th Dec 2025
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusi
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related re
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
10:01am, Wednesday, 17'th Dec 2025
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2 Recession-Proof Stocks to Watch in December
08:05am, Tuesday, 16'th Dec 2025
Walmart's low prices make it a go-to during recessions when people are cutting back on spending. Johnson & Johnson sells consumer health products that many people don't cut back on when adjusting thei
GAMMA Investing LLC Grows Stock Position in Johnson & Johnson $JNJ
06:46am, Tuesday, 16'th Dec 2025
GAMMA Investing LLC lifted its stake in Johnson and Johnson (NYSE: JNJ) by 10.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 54,5
Johnson & Johnson $JNJ Shares Sold by Cullen Capital Management LLC
06:02am, Tuesday, 16'th Dec 2025
Cullen Capital Management LLC reduced its position in shares of Johnson and Johnson (NYSE: JNJ) by 1.9% during the second quarter, according to the company in its most recent Form 13F filing with the
Johnson & Johnson (NYSE:JNJ) Shares Up 1.3% After Analyst Upgrade
01:30am, Tuesday, 16'th Dec 2025
Johnson and Johnson (NYSE: JNJ - Get Free Report)'s stock price was up 1.3% on Monday after Bank of America raised their price target on the stock from $204.00 to $220.00. Bank of America currently ha
Final Trade: JNJ, NVO, UBER, BMY
06:22pm, Monday, 15'th Dec 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
04:27pm, Monday, 15'th Dec 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. J
Johnson & Johnson Gets Target Hike, But BofA Flags Modest Pipeline Impact
01:08pm, Monday, 15'th Dec 2025
BofA raised Johnson and Johnson's price target to $220, citing steady growth, but sees limited upside from its pipeline through 2026.
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
12:56pm, Monday, 15'th Dec 2025
Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and improving risk-reward outlook.
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
11:51am, Monday, 15'th Dec 2025
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
